{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:29:12Z","timestamp":1793035752524,"version":"4.5.0"},"reference-count":134,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global burden of invasive fungal disease is substantial and escalating. Combination antifungal therapy (CAF) may improve patient outcomes by reducing development of resistance, improving drug penetration and rate of fungal clearance, and allowing for lower and less toxic antifungal drug doses; yet, increased cost, antagonism, drug-drug interactions, and toxicity are concerns. Clinical practice guidelines recommend antifungal monotherapy, rather than CAF, for most invasive fungal diseases due to a lack of comparative randomized clinical trials. An examination of the existing body of CAF research should frame new hypotheses and determine priorities for future CAF clinical trials. We performed a systematic review of CAF clinical studies for invasive candidiasis, cryptococcosis, invasive aspergillosis, and mucormycosis. Additionally, we summarized findings from animal models of CAF and assessed laboratory methods available to evaluate CAF efficacy. Future CAF trials should be prioritized according to animal models showing improved survival and observational clinical data supporting efficacy and safety.<\/jats:p>","DOI":"10.1093\/ofid\/ofae646","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T16:16:20Z","timestamp":1730132180000},"source":"Crossref","is-referenced-by-count":17,"title":["CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-886X","authenticated-orcid":false,"given":"Samantha E","family":"Jacobs","sequence":"first","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Microbiology and Molecular Biology Laboratories, Department of Pathology, Westchester Medical Center , Valhalla, New York ,","place":["USA"]},{"name":"Department of Pathology, Microbiology, and Immunology, New York Medical College , Valhalla, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2024112610471342300_ofae646-B1","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden killers: human fungal infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"2024112610471342300_ofae646-B2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.idc.2021.03.001","article-title":"Recent trends in the epidemiology of fungal infections","volume":"35","author":"Seagle","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2024112610471342300_ofae646-B3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/myc.13578","article-title":"Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors","volume":"66","author":"Chowdhary","year":"2023","journal-title":"Mycoses"},{"key":"2024112610471342300_ofae646-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mmcr.2020.02.003","article-title":"The robust and rapid role of molecular testing in precision fungal diagnostics: a case report","volume":"27","author":"Steinbrink","year":"2020","journal-title":"Med Mycol Case Rep"},{"key":"2024112610471342300_ofae646-B5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/femsre\/fuz015","article-title":"Recent trends in molecular diagnostics of yeast infections: from PCR to NGS","volume":"43","author":"Consortium OPATHY","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"2024112610471342300_ofae646-B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14737159.2022.2037423","article-title":"An overview of using fungal DNA for the diagnosis of invasive mycoses","volume":"22","author":"White","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"key":"2024112610471342300_ofae646-B7","doi-asserted-by":"crossref","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","article-title":"Economic burden of fungal diseases in the United States","volume":"9","author":"Benedict","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024112610471342300_ofae646-B8","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024112610471342300_ofae646-B9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/jac\/dku053","article-title":"Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed","volume":"69","author":"Valerio","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B10","doi-asserted-by":"crossref","first-page":"e0062921","DOI":"10.1128\/AAC.00629-21","article-title":"Implementation of pharmacist-driven antifungal stewardship program in a tertiary care hospital","volume":"65","author":"Kara","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"2024112610471342300_ofae646-B11","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 7","key":"2024112610471342300_ofae646-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024112610471342300_ofae646-B13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B14","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"2024112610471342300_ofae646-B15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024112610471342300_ofae646-B16","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024112610471342300_ofae646-B17","author":"World Health Organization"},{"key":"2024112610471342300_ofae646-B18"},{"key":"2024112610471342300_ofae646-B19","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S1473-3099(23)00731-4","article-title":"Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM","volume":"24","author":"Chang","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024112610471342300_ofae646-B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12281-010-0018-6","article-title":"Use of antifungal combination therapy: agents, order, and timing","volume":"4","author":"Johnson","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"2024112610471342300_ofae646-B21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: a strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2024112610471342300_ofae646-B22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14787210.2020.1705155","article-title":"Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction","volume":"18","author":"Coates","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024112610471342300_ofae646-B23","doi-asserted-by":"crossref","first-page":"ofae072","DOI":"10.1093\/ofid\/ofae072","article-title":"Optimizing the treatment of invasive candidiasis\u2014a case for combination therapy","volume":"11","author":"Wake","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024112610471342300_ofae646-B24","doi-asserted-by":"crossref","first-page":"e0215621","DOI":"10.1128\/aac.02156-21","article-title":"Challenges in the treatment of invasive aspergillosis in immunocompromised children","volume":"66","author":"Hsu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B25","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJM199705223362118","article-title":"Impact of combination therapy for HIV infection on inpatient census","volume":"336","author":"Torres","year":"1997","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"HIV-CAUSAL Collaboration","year":"2010","journal-title":"AIDS"},{"key":"2024112610471342300_ofae646-B27","doi-asserted-by":"crossref","first-page":"e01586-16.","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"2024112610471342300_ofae646-B28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2024112610471342300_ofae646-B29","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"2024112610471342300_ofae646-B31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B32","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B33","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/BF01713042","article-title":"A randomized study comparing fluconazole with amphotericin B\/5-flucytosine for the treatment of systemic Candida infections in intensive care patients","volume":"24","author":"Abele-Horn","year":"1996","journal-title":"Infection"},{"key":"2024112610471342300_ofae646-B35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/13693780500220415","article-title":"Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature","volume":"43","author":"Pelletier","year":"2005","journal-title":"Med Mycol"},{"key":"2024112610471342300_ofae646-B36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/089686080802800211","article-title":"Treatment of fungal peritonitis with a combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in continuous ambulatory peritoneal dialysis","volume":"28","author":"Wong","year":"2008","journal-title":"Perit Dial Int"},{"key":"2024112610471342300_ofae646-B37","doi-asserted-by":"crossref","first-page":"e00525","DOI":"10.1016\/j.idcr.2019.e00525","article-title":"Combination antifungal therapy for treatment of Candida parapsilosis prosthetic valve endocarditis and utility of T2Candida Panel: a case series","volume":"15","author":"Ahuja","year":"2019","journal-title":"IDCases"},{"key":"2024112610471342300_ofae646-B38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mmcr.2021.03.003","article-title":"Negative cerebrospinal fluid beta-d-glucan levels as an indicator for treatment cessation ahead of biochemical resolution: a case report of Candida glabrata meningitis","volume":"32","author":"Wee","year":"2021","journal-title":"Med Mycol Case Rep"},{"key":"2024112610471342300_ofae646-B39","doi-asserted-by":"crossref","first-page":"e02195-19","DOI":"10.1128\/AAC.02195-19","article-title":"In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak","volume":"64","author":"O\u2019Brien","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.3.4.573","article-title":"CNS pharmacokinetics of antifungal agents","volume":"3","author":"Kethireddy","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2024112610471342300_ofae646-B41","doi-asserted-by":"crossref","first-page":"e1002718","DOI":"10.1371\/journal.ppat.1002718","article-title":"Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata","volume":"8","author":"Singh-Babak","year":"2012","journal-title":"PLoS Pathog"},{"key":"2024112610471342300_ofae646-B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03183-4","article-title":"Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections","author":"Zhai","year":"2024","journal-title":"Nat Med"},{"key":"2024112610471342300_ofae646-B43","doi-asserted-by":"crossref","first-page":"e0005322","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-drug-resistant to four classes of antifungal agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B44","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B45","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B46","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"2024112610471342300_ofae646-B47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B48","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1086\/599112","article-title":"A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B49","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"key":"2024112610471342300_ofae646-B50","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-dose liposomal amphotericin B treatment for cryptococcal meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B52","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/jof7121098","article-title":"Combination therapy for HIV-associated cryptococcal meningitis\u2014a success story","volume":"7","author":"Hurt","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024112610471342300_ofae646-B53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.42.3.528","article-title":"Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis","volume":"42","author":"Diamond","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01216-08","article-title":"Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B55","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cir745","article-title":"Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis","volume":"54","author":"Loyse","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14737159.2023.2267977","article-title":"An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections","volume":"23","author":"Jenks","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"issue":"suppl 1","key":"2024112610471342300_ofae646-B57","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B58","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"2024112610471342300_ofae646-B59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.leu.2405065","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","author":"Raad","year":"2008","journal-title":"Leukemia"},{"key":"2024112610471342300_ofae646-B60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B62","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.21057","article-title":"Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis","volume":"103","author":"Kontoyiannis","year":"2005","journal-title":"Cancer"},{"key":"2024112610471342300_ofae646-B63","doi-asserted-by":"crossref","first-page":"e2012011","DOI":"10.4084\/mjhid.2012.011","article-title":"Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination","volume":"4","author":"Rojas","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2024112610471342300_ofae646-B64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B65","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","author":"Raad","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2024112610471342300_ofae646-B66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"2024112610471342300_ofae646-B67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024112610471342300_ofae646-B68","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024112610471342300_ofae646-B69","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024112610471342300_ofae646-B70","doi-asserted-by":"crossref","first-page":"ofae257","DOI":"10.1093\/ofid\/ofae257","article-title":"Meeting the therapeutic challenges of emergent and rare invasive fungal diseases through novel clinical trial designs","volume":"11","author":"Walsh","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2024112610471342300_ofae646-B71","doi-asserted-by":"crossref","first-page":"e1000412","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2024112610471342300_ofae646-B72","doi-asserted-by":"crossref","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"2024112610471342300_ofae646-B73","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1177\/0271678X20943823","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"40","author":"Percie du Sert","year":"2020","journal-title":"J Cereb Blood Flow Metab"},{"key":"2024112610471342300_ofae646-B74","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.47.7.2373-2375.2003","article-title":"Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis","volume":"47","author":"Graybill","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B75","doi-asserted-by":"crossref","first-page":"e57672","DOI":"10.1371\/journal.pone.0057672","article-title":"Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"2024112610471342300_ofae646-B76","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/jof8101077","article-title":"Antifungal combinations against Candida species: from bench to bedside","volume":"8","author":"Fioriti","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2024112610471342300_ofae646-B77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/AAC.45.2.485-494.2001","article-title":"Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B78","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jac\/dkg230","article-title":"Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans","volume":"51","author":"Hossain","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B79","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.49.6.2546-2549.2005","article-title":"Caspofungin in combination with amphotericin B against Candida glabrata","volume":"49","author":"Barchiesi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B80","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1128\/AAC.49.12.4895-4902.2005","article-title":"Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin","volume":"49","author":"Olson","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/AAC.50.1.113-120.2006","article-title":"Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis","volume":"50","author":"Schwarz","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B82","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/AAC.48.3.985-991.2004","article-title":"Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis","volume":"48","author":"Larsen","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B83","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.44.9.2435-2441.2000","article-title":"Interactions between triazoles and amphotericin B against Cryptococcus neoformans","volume":"44","author":"Barchiesi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B84","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1179\/joc.2002.14.4.351","article-title":"Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model","volume":"14","author":"Hossain","year":"2002","journal-title":"J Chemother"},{"key":"2024112610471342300_ofae646-B85","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11046-010-9375-5","article-title":"Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans","volume":"171","author":"Silva","year":"2011","journal-title":"Mycopathologia"},{"key":"2024112610471342300_ofae646-B86","first-page":"457","article-title":"Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis","volume":"55","author":"Martin-Vicente","year":"2017","journal-title":"Med Mycol"},{"key":"2024112610471342300_ofae646-B87","doi-asserted-by":"crossref","first-page":"e00305-17","DOI":"10.1128\/AAC.00305-17","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B88","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1128\/AAC.00329-09","article-title":"Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by bliss independence drug interaction analysis","volume":"53","author":"Petraitis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B89","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/infdis\/151.5.902","article-title":"The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis","volume":"151","author":"Schaffner","year":"1985","journal-title":"J Infect Dis"},{"key":"2024112610471342300_ofae646-B90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1128\/AAC.01462-15","article-title":"In vivo synergy of amphotericin B plus posaconazole in murine aspergillosis","volume":"60","author":"Martin-Vicente","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B91","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/jac\/dkl236","article-title":"Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis","volume":"58","author":"Clemons","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13693780500148350","article-title":"Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis","volume":"44","author":"Clemons","year":"2006","journal-title":"Med Mycol"},{"key":"2024112610471342300_ofae646-B93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1128\/AAC.50.2.422-427.2006","article-title":"Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-\/- mouse model of chronic granulomatous disease","volume":"50","author":"Dennis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B94","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"Gebremariam","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B95","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","author":"Ibrahim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B96","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","article-title":"Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae","volume":"52","author":"Rodr\u00edguez","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B97","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B98","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B99","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/589305","article-title":"Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae","volume":"198","author":"Lamaris","year":"2008","journal-title":"J Infect Dis"},{"key":"2024112610471342300_ofae646-B101","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B102","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/jof7020113","article-title":"Techniques for the assessment of in vitro and in vivo antifungal combinations","volume":"7","author":"Bidaud","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2024112610471342300_ofae646-B103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365540600786564","article-title":"Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine","volume":"39","author":"Bhat","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"2024112610471342300_ofae646-B104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11046-022-00621-0","article-title":"Aspergillus tubingensis endocarditis: a case report and review of the literature","volume":"187","author":"Born","year":"2022","journal-title":"Mycopathologia"},{"key":"2024112610471342300_ofae646-B105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-002-0877-z","article-title":"Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine","volume":"22","author":"Howden","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024112610471342300_ofae646-B106","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.diagmicrobio.2008.08.003","article-title":"Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine","volume":"62","author":"Krishnan-Natesan","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024112610471342300_ofae646-B107","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/jof9040434","article-title":"In vitro-in vivo correlation of posaconazole-amphotericin B combination against Candida albicans: in vitro interacting concentrations are associated with in vivo free drug levels","volume":"9","author":"Meletiadis","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024112610471342300_ofae646-B108","doi-asserted-by":"crossref","first-page":"e0164522","DOI":"10.1128\/aac.01645-22","article-title":"Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro","volume":"66","author":"John","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11046-015-9899-9","article-title":"Anti-Candida activity of new azole derivatives alone and in combination with fluconazole","volume":"180","author":"Shi","year":"2015","journal-title":"Mycopathologia"},{"key":"2024112610471342300_ofae646-B110","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1128\/AAC.00045-12","article-title":"In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp","volume":"56","author":"Planche","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B111","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diagmicrobio.2011.05.007","article-title":"In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp","volume":"71","author":"Venturini","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024112610471342300_ofae646-B112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/13693786.2010.530300","article-title":"In vitro interactions among echinocandins against Aspergillus fumigatus: lack of concordance among methods","volume":"49","author":"Ben-Ami","year":"2011","journal-title":"Med Mycol"},{"key":"2024112610471342300_ofae646-B113","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.01160-07","article-title":"In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans","volume":"52","author":"Cuenca-Estrella","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B114","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/13693780801975576","article-title":"Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus","volume":"46","author":"Arikan","year":"2008","journal-title":"Med Mycol"},{"key":"2024112610471342300_ofae646-B115","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1128\/AAC.00162-06","article-title":"In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B116","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1128\/AAC.49.8.3572-3574.2005","article-title":"In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp and Fusarium spp","volume":"49","author":"Philip","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B117","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jac\/dki343","article-title":"Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro","volume":"56","author":"Lewis","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B118","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1128\/AAC.49.3.1232-1235.2005","article-title":"Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus","volume":"49","author":"Cuenca-Estrella","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B119","first-page":"57","article-title":"Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp","volume":"83","author":"Srimuang","year":"2000","journal-title":"J Med Assoc Thai"},{"key":"2024112610471342300_ofae646-B120","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jac\/41.1.59","article-title":"In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans","volume":"41","author":"Barchiesi","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"2024112610471342300_ofae646-B121","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/AAC.36.2.486","article-title":"Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion","volume":"36","author":"Hanson","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B122","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"2024112610471342300_ofae646-B123","volume-title":"Performance standards for antifungal susceptibility testing of yeasts: CLSI supplement M60","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"2024112610471342300_ofae646-B124","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/AAC.00999-09","article-title":"Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus","volume":"54","author":"Meletiadis","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B125","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1128\/AAC.04545-14","article-title":"Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint","volume":"59","author":"Ren","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B126","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1128\/AAC.01510-09","article-title":"Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis","volume":"55","author":"Chaturvedi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B127","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.00574-07","article-title":"Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei","volume":"52","author":"Chaturvedi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610471342300_ofae646-B128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/jof8090967","article-title":"Multicenter collaborative study of the interaction of antifungal combinations against Candida spp by Loewe additivity and Bliss independence-based response surface analysis","volume":"8","author":"Meletiadis","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2024112610471342300_ofae646-B129","doi-asserted-by":"crossref","first-page":"e071108","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"2024112610471342300_ofae646-B130","doi-asserted-by":"crossref","first-page":"507","DOI":"10.12688\/f1000research.28327.1","article-title":"Novel antifungal agents in clinical trials","volume":"10","author":"Jacobs","year":"2021","journal-title":"F1000Res"},{"key":"2024112610471342300_ofae646-B131","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"2024112610471342300_ofae646-B132","doi-asserted-by":"crossref","first-page":"1018202","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"},{"key":"2024112610471342300_ofae646-B133","doi-asserted-by":"crossref","first-page":"900522","DOI":"10.3389\/fimmu.2022.900522","article-title":"Case report: immune checkpoint blockade plus interferon-gamma add-on antifungal therapy in the treatment of refractory COVID-associated pulmonary aspergillosis and cerebral mucormycosis","volume":"13","author":"Serris","year":"2022","journal-title":"Front Immunol"},{"key":"2024112610471342300_ofae646-B134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae646\/60241021\/ofae646.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae646\/60793736\/ofae646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae646\/60793736\/ofae646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:48:41Z","timestamp":1732600121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae646\/7852653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae646","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.10.24310241","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"ofae646"}}